Evaxion Biotech AS (EVAX)
2.64
+0.05
(+1.93%)
USD |
NASDAQ |
Nov 04, 16:00
2.64
0.00 (0.00%)
After-Hours: 20:00
Evaxion Biotech Net Income (Quarterly): -1.935M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -1.935M |
June 30, 2024 | -6.198M |
March 31, 2024 | 1.194M |
December 31, 2023 | -4.523M |
September 30, 2023 | -5.678M |
June 30, 2023 | -5.683M |
March 31, 2023 | -6.241M |
December 31, 2022 | -6.872M |
September 30, 2022 | -5.74M |
June 30, 2022 | -4.768M |
Date | Value |
---|---|
March 31, 2022 | -5.791M |
December 31, 2021 | -8.37M |
September 30, 2021 | -5.25M |
June 30, 2021 | -6.819M |
March 31, 2021 | -4.093M |
December 31, 2020 | -4.269M |
September 30, 2020 | -4.01M |
June 30, 2020 | -3.64M |
March 31, 2020 | -3.099M |
December 31, 2019 | -3.519M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-8.37M
Minimum
Dec 2021
1.194M
Maximum
Mar 2024
-4.765M
Average
-5.009M
Median
Net Income (Quarterly) Benchmarks
Ascendis Pharma AS | -117.77M |
Novo Nordisk AS | 2.894B |
DBV Technologies SA | -33.12M |
Adaptimmune Therapeutics PLC | 69.52M |
Akari Therapeutics PLC | -7.558M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 3.017M |
Total Expenses (Quarterly) | 4.748M |
EPS Diluted (Quarterly) | -0.40 |
Enterprise Value | 9.871M |
Profit Margin (Quarterly) | -64.14% |
Earnings Yield | -106.1% |
Normalized Earnings Yield | -94.46 |